Creative Biolabs is a well-recognized expert in the field of antibody generation and production. Especially, we have launched a series of in vitro diagnostic (IVD) antibody development services for different infections and diseases, including sepsis. Scientific progress has resulted in the discovery of novel disease biomarkers to fulfill the need for quicker, more specific and more accurate diagnosis of sepsis. Particularly, we provide IVD antibody development services against the CD14 marker.
CD14
CD14, the LPS (lipopolysaccharide) receptor, is initially a leukocyte differentiation antigen present on the surface of monocytes, macrophages and other cells, mediating LPS-like cellular responses. CD14 was discovered by TODD on the surface of human monocytes for the first time in 1981. The gene is located on the long arm 5q23-q31 of human chromosome 5 and contains approximately 1338 nucleotide residues. From nucleotides 76 to 1200, a polypeptide chain of 375 amino acid residues is encoded. CD14 is an important receptor molecule involved in the identification and response of pathogenic microorganisms.
Fig.1 CD14 assists in the identification of LPS by TLR-4. (Solov'eva., 2013)
CD14 as Marker of Sepsis
In recent years, considerable progress has been made in understanding the molecular and cellular mechanisms of gram-negative sepsis and endotoxin shock. These clinical syndromes are caused by the accumulation of endotoxin LPS in the host's blood. It is released from pathogenic bacterial cells during the systemic bacterial infection or released from the normal bacterial communities in the intestinal lumen. By interacting with a specific receptor TLR-4 on host effector cells, CD14 is an accessory protein that LPS binds to TLR-4. Stimulation of TLR-4 triggers a response to the adaptor molecule MyD88 (bone marrow differentiation primary response protein 88). MyD88-dependent signaling pathway leads to the activation of nuclear factor-κβ (NF-κβ), which regulates the expression of target genes encoding pro-inflammatory mediators. Excessive stimulation of the receptor may lead to uncontrolled systemic inflammation and eventually to sepsis.
Fig.2 CD14 is a receptor of the LPS (Lipopolysaccharide). (Nikolay, N., 2017)
IVD Antibody Development Services for CD14 Marker
Based on the rapid development of IVD technology and novel biomarkers, IVD antibodies are extensively used for disease screening and therapeutic monitoring. Diverse immunoassays are applied for disease diagnosis, including lateral flow assay, immunochemistry, sandwich ELISA, etc. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to deliver high-quality IVD antibody development services targeting numerous biomarkers of sepsis, such as CD14. With years of devotion and accumulation in this particular field, Creative Biolabs is confident in offering you the best products and services.
If you are interested in our IVD antibody discovery services, please contact us for more details.
Reference
For Research Use Only.
